656 related articles for article (PubMed ID: 26964571)
1. HDAC Inhibitors Enhance T-Cell Chemokine Expression and Augment Response to PD-1 Immunotherapy in Lung Adenocarcinoma.
Zheng H; Zhao W; Yan C; Watson CC; Massengill M; Xie M; Massengill C; Noyes DR; Martinez GV; Afzal R; Chen Z; Ren X; Antonia SJ; Haura EB; Ruffell B; Beg AA
Clin Cancer Res; 2016 Aug; 22(16):4119-32. PubMed ID: 26964571
[TBL] [Abstract][Full Text] [Related]
2. Potential Predictive Value of
Dong ZY; Zhong WZ; Zhang XC; Su J; Xie Z; Liu SY; Tu HY; Chen HJ; Sun YL; Zhou Q; Yang JJ; Yang XN; Lin JX; Yan HH; Zhai HR; Yan LX; Liao RQ; Wu SP; Wu YL
Clin Cancer Res; 2017 Jun; 23(12):3012-3024. PubMed ID: 28039262
[No Abstract] [Full Text] [Related]
3. HDAC inhibitors with PD-1 blockade: a promising strategy for treatment of multiple cancer types?
Beg AA; Gray JE
Epigenomics; 2016 Aug; 8(8):1015-7. PubMed ID: 27410519
[No Abstract] [Full Text] [Related]
4. Timing of PD-1 Blockade Is Critical to Effective Combination Immunotherapy with Anti-OX40.
Messenheimer DJ; Jensen SM; Afentoulis ME; Wegmann KW; Feng Z; Friedman DJ; Gough MJ; Urba WJ; Fox BA
Clin Cancer Res; 2017 Oct; 23(20):6165-6177. PubMed ID: 28855348
[No Abstract] [Full Text] [Related]
5. Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers.
Gray MJ; Gong J; Hatch MM; Nguyen V; Hughes CC; Hutchins JT; Freimark BD
Breast Cancer Res; 2016 May; 18(1):50. PubMed ID: 27169467
[TBL] [Abstract][Full Text] [Related]
6. HDAC Inhibition Upregulates PD-1 Ligands in Melanoma and Augments Immunotherapy with PD-1 Blockade.
Woods DM; Sodré AL; Villagra A; Sarnaik A; Sotomayor EM; Weber J
Cancer Immunol Res; 2015 Dec; 3(12):1375-85. PubMed ID: 26297712
[TBL] [Abstract][Full Text] [Related]
7. Peripheral CX3CR1
Li C; Zhang Z; Cai Q; Zhao Q; Wu H; Li J; Liu Y; Zhao X; Liu J; Ping Y; Shan J; Yang S; Zhang Y
Oncoimmunology; 2024; 13(1):2355684. PubMed ID: 38798746
[TBL] [Abstract][Full Text] [Related]
8. The Combined Effect of FGFR Inhibition and PD-1 Blockade Promotes Tumor-Intrinsic Induction of Antitumor Immunity.
Palakurthi S; Kuraguchi M; Zacharek SJ; Zudaire E; Huang W; Bonal DM; Liu J; Dhaneshwar A; DePeaux K; Gowaski MR; Bailey D; Regan SN; Ivanova E; Ferrante C; English JM; Khosla A; Beck AH; Rytlewski JA; Sanders C; Laquerre S; Bittinger MA; Kirschmeier PT; Packman K; Janne PA; Moy C; Wong KK; Verona RI; Lorenzi MV
Cancer Immunol Res; 2019 Sep; 7(9):1457-1471. PubMed ID: 31331945
[TBL] [Abstract][Full Text] [Related]
9. Assessment of new HDAC inhibitors for immunotherapy of malignant pleural mesothelioma.
Bensaid D; Blondy T; Deshayes S; Dehame V; Bertrand P; Grégoire M; Errami M; Blanquart C
Clin Epigenetics; 2018; 10():79. PubMed ID: 29946373
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of histone lysine-specific demethylase 1 elicits breast tumor immunity and enhances antitumor efficacy of immune checkpoint blockade.
Qin Y; Vasilatos SN; Chen L; Wu H; Cao Z; Fu Y; Huang M; Vlad AM; Lu B; Oesterreich S; Davidson NE; Huang Y
Oncogene; 2019 Jan; 38(3):390-405. PubMed ID: 30111819
[TBL] [Abstract][Full Text] [Related]
11. CU06-1004-Induced Vascular Normalization Improves Immunotherapy by Modulating Tumor Microenvironment
Park S; Oh JH; Park DJ; Zhang H; Noh M; Kim Y; Kim YS; Kim H; Kim YM; Ha SJ; Kwon YG
Front Immunol; 2020; 11():620166. PubMed ID: 33584714
[TBL] [Abstract][Full Text] [Related]
12. PD-1/PD-L1 Blockade Enhances T-cell Activity and Antitumor Efficacy of Imatinib in Gastrointestinal Stromal Tumors.
Seifert AM; Zeng S; Zhang JQ; Kim TS; Cohen NA; Beckman MJ; Medina BD; Maltbaek JH; Loo JK; Crawley MH; Rossi F; Besmer P; Antonescu CR; DeMatteo RP
Clin Cancer Res; 2017 Jan; 23(2):454-465. PubMed ID: 27470968
[TBL] [Abstract][Full Text] [Related]
13. Determination of poor prognostic immune features of tumour microenvironment in non-smoking patients with lung adenocarcinoma.
Kinoshita T; Kudo-Saito C; Muramatsu R; Fujita T; Saito M; Nagumo H; Sakurai T; Noji S; Takahata E; Yaguchi T; Tsukamoto N; Hayashi Y; Kaseda K; Kamiyama I; Ohtsuka T; Tomizawa K; Shimoji M; Mitsudomi T; Asamura H; Kawakami Y
Eur J Cancer; 2017 Nov; 86():15-27. PubMed ID: 28950145
[TBL] [Abstract][Full Text] [Related]
14. [pemetrexed + sildenafil], via autophagy-dependent HDAC downregulation, enhances the immunotherapy response of NSCLC cells.
Booth L; Roberts JL; Poklepovic A; Dent P
Cancer Biol Ther; 2017 Sep; 18(9):705-714. PubMed ID: 28812434
[TBL] [Abstract][Full Text] [Related]
15. Fractionated Radiation Therapy Stimulates Antitumor Immunity Mediated by Both Resident and Infiltrating Polyclonal T-cell Populations when Combined with PD-1 Blockade.
Dovedi SJ; Cheadle EJ; Popple AL; Poon E; Morrow M; Stewart R; Yusko EC; Sanders CM; Vignali M; Emerson RO; Robins HS; Wilkinson RW; Honeychurch J; Illidge TM
Clin Cancer Res; 2017 Sep; 23(18):5514-5526. PubMed ID: 28533222
[No Abstract] [Full Text] [Related]
16. Prior exposure of pancreatic tumors to [sorafenib + vorinostat] enhances the efficacy of an anti-PD-1 antibody.
Booth L; Roberts JL; Poklepovic A; Dent P
Cancer Biol Ther; 2019; 20(1):109-121. PubMed ID: 30142009
[TBL] [Abstract][Full Text] [Related]
17.
De La Maza L; Wu M; Wu L; Yun H; Zhao Y; Cattral M; McCart A; Cho BJ; de Perrot M
Clin Cancer Res; 2017 Sep; 23(18):5502-5513. PubMed ID: 28606922
[No Abstract] [Full Text] [Related]
18. HHLA2, a New Immune Checkpoint Member of the B7 Family, Is Widely Expressed in Human Lung Cancer and Associated with EGFR Mutational Status.
Cheng H; Janakiram M; Borczuk A; Lin J; Qiu W; Liu H; Chinai JM; Halmos B; Perez-Soler R; Zang X
Clin Cancer Res; 2017 Feb; 23(3):825-832. PubMed ID: 27553831
[TBL] [Abstract][Full Text] [Related]
19. Anti-PD-1 increases the clonality and activity of tumor infiltrating antigen specific T cells induced by a potent immune therapy consisting of vaccine and metronomic cyclophosphamide.
Weir GM; Hrytsenko O; Quinton T; Berinstein NL; Stanford MM; Mansour M
J Immunother Cancer; 2016; 4():68. PubMed ID: 27777777
[TBL] [Abstract][Full Text] [Related]
20. Biomarkers for PD-1/PD-L1 Blockade Therapy in Non-Small-cell Lung Cancer: Is PD-L1 Expression a Good Marker for Patient Selection?
Chae YK; Pan A; Davis AA; Raparia K; Mohindra NA; Matsangou M; Giles FJ
Clin Lung Cancer; 2016 Sep; 17(5):350-361. PubMed ID: 27137346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
